LONDON and NEW YORK—OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), has announced that it has received $1.4 million in non-dilutive funding. This significant financial funding strengthens the company’s ability to advance its innovative pipeline without diluting shareholder value, according to the announcement. The company stated that the funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO’s lead program, OK-101 focused on treating NCP.

OKYO is focused on the development of OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. The company said its main focus is clinical development of OK-101 to treat dry eye disease (DED). OK-101 is a drug candidate currently in clinical trials, designed to treat DED and NCP by targeting the ChemR23 G-protein coupled receptor on immune cells in the eye.

“Securing $1.4 million in non-dilutive funding marks an important milestone for OKYO Pharma. This financial boost will significantly contribute to our mission of developing groundbreaking treatments for ophthalmic diseases,” commented Dr. Gary S. Jacob, CEO of OKYO Pharma. “Importantly, this funding supports our ability to continue creating value for our shareholders while advancing our clinical programs. We remain committed to driving innovation and delivering solutions that improve patient outcomes.”